Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide.
Savelli G, Bertagna F, Franco F, Dognini L, Bosio G, Migliorati E, Rodella C, Biasiotto G, Bettinsoli G, Minari C, Zaniboni A, Ferrari C, Tomassetti P, Ferrari V, Giubbini R.
Savelli G, et al. Among authors: biasiotto g.
Cancer. 2012 Jun 1;118(11):2915-24. doi: 10.1002/cncr.26616. Epub 2011 Oct 21.
Cancer. 2012.
PMID: 22020784
Free article.
Clinical Trial.